APG Asset Management N.V. Acquires 1,400 Shares of Masimo Co. (NASDAQ:MASI)

APG Asset Management N.V. grew its holdings in shares of Masimo Co. (NASDAQ:MASI) by 0.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 321,064 shares of the medical equipment provider’s stock after acquiring an additional 1,400 shares during the quarter. APG Asset Management N.V.’s holdings in Masimo were worth $65,640,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of MASI. Ameritas Investment Company LLC bought a new stake in shares of Masimo during the 1st quarter valued at about $25,000. IFP Advisors Inc boosted its position in shares of Masimo by 535.3% during the 2nd quarter. IFP Advisors Inc now owns 108 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 91 shares during the last quarter. Isthmus Partners LLC bought a new stake in shares of Masimo during the 2nd quarter valued at about $36,000. Archer Investment Corp boosted its position in shares of Masimo by 28.0% during the 2nd quarter. Archer Investment Corp now owns 183 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 40 shares during the last quarter. Finally, Cullen Frost Bankers Inc. bought a new stake in shares of Masimo during the 2nd quarter valued at about $70,000. Hedge funds and other institutional investors own 82.24% of the company’s stock.

Shares of Masimo stock opened at $278.64 on Thursday. The business’s 50 day simple moving average is $274.07 and its two-hundred day simple moving average is $250.59. The stock has a market capitalization of $15.34 billion, a P/E ratio of 72.19 and a beta of 0.79. Masimo Co. has a one year low of $205.10 and a one year high of $288.27.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Monday, July 26th. The medical equipment provider reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.04. The business had revenue of $300.78 million for the quarter, compared to analysts’ expectations of $295.60 million. Masimo had a return on equity of 15.17% and a net margin of 19.00%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.85 EPS. As a group, sell-side analysts forecast that Masimo Co. will post 3.85 earnings per share for the current year.

A number of analysts recently weighed in on MASI shares. Raymond James started coverage on Masimo in a research report on Tuesday. They issued a “market perform” rating for the company. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $298.00 target price for the company in a research report on Monday, September 27th. Finally, Piper Sandler boosted their target price on Masimo from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Masimo presently has a consensus rating of “Buy” and an average target price of $293.80.

Masimo Company Profile

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories.

See Also: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.